1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
bioMerieux SA

bioMerieux SA

88.65
EUR
+2.05
(+2.37%)
8.07BMarket Cap
Mar 04Next Earn
bioMerieux SA
GETTEX:EYWN
(Gettex)

Recent

price

88.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
11.46
12.06
13.28
13.4
14.35
16.59
17.82
19.41
20.56
22.61
26.39
28.55
30.43
31.1
33.8
34.49
- -
Revenue per Share
1.35
1.34
1.14
1.39
1.14
0.93
1.52
2.02
2.18
2.31
3.42
5.08
3.84
3.03
3.67
3.37
- -
Basic EPS, GAAP
0.64
0.97
1.11
0.92
1.18
0.86
0.87
2.9
1.47
1.14
2.58
4.52
1.6
0.91
2.73
3.84
- -
Free Cash Flow per Basic Share
0.31
0.33
0.33
0.33
0.33
0.33
0.33
0.33
0.34
0.35
0.19
0.62
0.86
0.85
0.85
0.9
- -
Dividend per Share
8.21
9.03
9.75
10.66
11.67
12.63
13.72
14.71
16.37
18.63
20.57
26.31
30.56
31.76
35.66
34.77
36.51
Book Value per Share
5.58
4.64
5.77
6.81
4.08
4.72
5.56
7.32
6.78
8.82
11.6
17.17
18.37
21.37
25.29
25.2
26.55
Tangible Book Value per Share
118
118
118
118
118
118
118
118
118
118
118
118
118
118
118
118
118
Basic Weighted Avg Shares
1,357
1,427
1,570
1,588
1,698
1,965
2,103
2,288
2,421
2,675
3,118
3,376
3,589
3,675
3,980
4,070
- -
Sales/Revenue/Turnover
18.69
18.05
16.58
16.52
13.35
13.23
14.16
14.63
15.02
13.85
19.64
25
17.43
15.48
16.03
17.07
- -
Operating Margin (%)
88
85
94
91
105
120
143
141
177
190
211
248
248
259
302
307
- -
Depreciation Expense
160
158
134
164
135
111
179
238
257
273
404
601
452
358
432
398
- -
Net Income, GAAP
33.72
32.48
39.98
32.2
27.57
37.32
30.78
18.63
20.31
22.4
23.17
22.67
24.13
26.17
26.64
24.5
- -
Effective Tax Rate (%)
11.79
11.08
8.56
10.35
7.94
5.62
8.52
10.41
10.59
10.2
12.97
17.8
12.61
9.73
10.86
9.77
- -
Profit Margin (%)
309
218
356
731
416
413
423
630
518
268
738
1,237
1,086
1,118
1,367
1,476
1,467
Working Capital
8
13
10
305
306
309
365
391
525
154
352
363
318
355
349
330
189
LT Debt
976
1,076
1,160
1,267
1,389
1,503
1,621
1,737
2,002
2,255
2,481
3,164
3,643
3,752
4,211
4,106
4,299
Total Equity
16.89
13.59
10
10.75
7.86
6.07
8.84
10.77
10.27
9.48
13.2
16.69
10.49
7.07
8.81
7.77
- -
Return on Invested Capital (%)
17.4
13.96
10.88
11.33
8.45
6.69
9.68
11.77
11.25
10.65
14.64
18.55
12.02
9.6
10.05
8.85
- -
Return on Capital (%)
18.04
15.51
12.1
13.61
10.21
7.69
11.5
14.19
13.99
13.2
17.45
21.69
13.47
9.72
10.86
9.57
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
172
131
233
LT Borrowings
213
211
66
LT Finance Leases
121
119
122
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
118
118
118
Market Capitalization
13,897
12,990
8,074

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
2,277
2,540
2,595
Cash, Cash Equivalents & STI
381
570
658
Accounts Receivable, Net
688
766
715
Inventories
974
960
975
Total Current Liabilities
1,005
1,065
1,128
Payables & Accruals
- -
- -
- -
ST Debt
172
131
233
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.84%
11.08%
-2.49%
Free Cash Flow
49.61%
41.66%
40.93%
Net Income, GAAP
17.31%
3.16%
-8.03%
Sales/Revenue/Turnover
7.63%
5.51%
2.26%
Total Cash Common Dividend
- -
- -
5.89%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3,980
2025
- -
- -
4,070
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3.67
2025
- -
- -
3.37
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.85
2025
- -
- -
0.9
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
bioMérieux S.A. is a French multinational biotechnology company specializing in in vitro diagnostic solutions for infectious diseases, cancer screening, cardiovascular emergencies, and industrial applications such as food safety, pharmaceuticals, and cosmetics. Founded in 1963 and headquartered in Marcy-l'Étoile, France, bioMérieux designs, develops, manufactures, and markets diagnostic equipment, reagents, software, and services. Its core products include molecular biology solutions such as the BioFire FilmArray system, immunoassays, microbiology solutions like VIDAS, VITEK systems, and advanced point-of-care testing technologies including the SPOTFIRE platform. The company operates in over 44 countries and serves more than 160 countries worldwide through a large distribution network. Recent significant developments include the acquisition of Neoprospecta in early 2025, enhancing bioMérieux's Data & Genomics capabilities particularly in Brazil and Latin America for pathogen investigation and contamination prevention in food and pharmaceutical industries. It also acquired SpinChip Diagnostics in late 2025 to strengthen its point-of-care diagnostics portfolio with advanced immunoassay technology. bioMérieux launched the GENE-UP TYPER diagnostic solution for rapid root cause analysis of Listeria monocytogenes contamination in food industries and the WatchFire molecular PCR test for detecting viruses and bacteria in wastewater. Furthermore, the company signed an exclusive worldwide distribution agreement with Oxford Nanopore Technologies for the AmPORE TB® assay, a molecular sequencing test addressing Mycobacterium tuberculosis and antimicrobial resistance detection. In 2024, bioMérieux received multiple FDA approvals including for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, enabling rapid multiplex PCR-based diagnostics with CLIA-waiver for point-of-care use. The company pursued its GO- 28 strategic plan focusing on innovation, achieving double-digit organic sales growth driven by microbiology reagents, non-respiratory and respiratory BIOFIRE panels, and expanded industrial application sales. bioMérieux continues to drive development in molecular diagnostics, immunoassays, software, and integrated diagnostic systems while maintaining a robust global commercial infrastructure and innovation pipeline in infectious disease diagnostics and industrial microbiology safety solutions.

Company News

Company News APIChatGPT

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Stock Now Rated “Reduce” by Sell-Side Analysts

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript

  • defenseworld.net

    Analyzing HealthEquity (NASDAQ:HQY) and bioMerieux (OTCMKTS:BMXMF)

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Time to Buy?

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Sees Unusually-High Trading Volume – Time to Buy?

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    bioMérieux: Pioneering In Vitro Diagnostics

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript

  • zacks.com

    4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis